NG
NKTR icon

NatWest Group’s Nektar Therapeutics NKTR Stock Holding History

NatWest Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,990
Closed -$492K – 270
2015
Q3 		$492K Buy
+2,990
New +$529K 0.01% 282
2015
Q2 		– Sell
-2,990
Closed -$493K – 413
2015
Q1 		$493K Sell
2,990
-144
-5% -$29.6K 0.01% 322
2014
Q4 		$729 Sell
3,134
-3,331
-52% -$712K 0.01% 253
2014
Q3 		$1.17K Buy
6,465
+155
+2% +$29.7K 0.01% 239
2014
Q2 		$1.21M Buy
6,310
+632
+11% +$112K 0.05% 243
2014
Q1 		$1.03M Sell
5,678
-895
-14% -$177K 0.05% 243
2013
Q4 		$1.12M Buy
6,573
+1,314
+25% +$212K 0.03% 407
2013
Q3 		$824K Sell
5,259
-332
-6% -$61.4K 0.02% 501
2013
Q2 		$969K Buy
+5,591
New +$858K 0.01% 471

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NatWest Group's NKTR Position: Q4 2015 in Review

NatWest Group sold out of Nektar Therapeutics (NKTR) in Q4 2015, closing a stake of 2,990 shares — an estimated $492K sold.

NatWest Group first reported a position in NKTR in Q2 2013 and held it in 9 quarters. The position peaked at $1.21M in Q2 2014. 179 funds tracked by Wall St. Rank hold NKTR as of Q4 2015.

  • NatWest Group reported no remaining Nektar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • NatWest Group sold 2,990 Nektar Therapeutics shares in Q4 2015, an estimated $492K.
  • NatWest Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 9 quarters.
  • NatWest Group's Nektar Therapeutics position peaked at $1.21M in Q2 2014.
  • 179 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.